title: [Efficacy and safety of aprepitant in patients with breast cancer].
abstract: We retrospectively analyzed the efficacy and safety of aprepitant in breast cancer patients who were treated with FEC(5- fluorouracil, epirubicin, cyclophosphamide)or EC(epirubicin, cyclophosphamide). We divided patients into two groups according to the aprepitant approval period. The rate of severe nausea(@Grade 2)was significantly less in patients with aprepitant(acute 10. 0%, delayed 15. 0%)than those without aprepitant(acute 29. 1%, delayed 30. 9%). Complete response( no vomiting and no use of rescue therapy)in the acute phase was significantly higher in the aprepitant pretreated group than in the no aprepitant group(82. 5% vs 61. 8%, respectively). Moreover, complete response in the delayed phase was also higher in the aprepitant group than in the no aprepitant group(82. 5%vs 58. 2%, respectively). Pre-treatment with aprepitant did not increase adverse events including constipation and elevation of alanine transaminase. The aprepitant was effective in terms of prevention of chemotherapy-induced nausea and vomiting in patients treated with an anthracycline- based regimen.
authors.affiliation: Division of Pharmacy, Shikoku Cancer Center, Aichi Cancer Center Research Institute.
authors.forename: Hisashi
authors.initials: H
authors.lastname: Tagashira
authors.forename: Tetsuaki
authors.initials: T
authors.lastname: Matsuhisa
authors.forename: Isao
authors.initials: I
authors.lastname: Oze
authors.forename: Sachiko
authors.initials: S
authors.lastname: Kiyoto
authors.forename: Mina
authors.initials: M
authors.lastname: Takahashi
authors.forename: Fumikata
authors.initials: F
authors.lastname: Hara
authors.forename: Daisuke
authors.initials: D
authors.lastname: Takabatake
authors.forename: Seiki
authors.initials: S
authors.lastname: Takashima
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Aogi
authors.forename: Shozo
authors.initials: S
authors.lastname: Osumi
authors.forename: Hisae
authors.initials: H
authors.lastname: Eguchi
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D000077608:Aprepitant; D001943:Breast Neoplasms / Q000188:drug therapy; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D015251:Epirubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use*; D009325:Nausea / Q000517:prevention & control*; D012189:Retrospective Studies
chemical_list: D009025:Morpholines; D000077608:Aprepitant; D015251:Epirubicin; D003520:Cyclophosphamide; D005472:Fluorouracil